<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547232</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-1413</org_study_id>
    <nct_id>NCT03547232</nct_id>
  </id_info>
  <brief_title>A Trial of Indomethacin in Acute Pancreatitis</brief_title>
  <official_title>A Randomized Controlled Trial of Indomethacin in Acute Pancreatitis- Effectiveness and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis (AP) is an inflammatory condition of the pancreas following the activated&#xD;
      pancreatic enzymes induced by varied causes, with or without other organ(s) dysfunction. The&#xD;
      production and release of inflammatory factors is generally considered as the key factor of&#xD;
      pathogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly applied&#xD;
      agents for inflammatory diseases. A series studies have proved that indomethacin can reduce&#xD;
      the risk of post-endoscopic retrograde cholangiopancreatography (ERCP), but high-quality&#xD;
      evidence is still lacking in the field of effectiveness of NSAIDs to treat, rather than&#xD;
      prevent, other types of AP. Majority of animal experiments showed that NSAIDs had protective&#xD;
      effects for organ functions, but the results of several preliminary clinical studies were&#xD;
      inconsistent. Randomized controlled trials are eagerly awaited to elucidate its effects on&#xD;
      AP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence rate of organ dysfunction</measure>
    <time_frame>1 week</time_frame>
    <description>Accumulation of varied organ dysfunction, especially the cardiovascular, renal and respiratory systems</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence rate of pancreatic necrosis</measure>
    <time_frame>1 month</time_frame>
    <description>Accumulation of the key local complication of acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of ICU admission</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of critical severe acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month</time_frame>
    <description>The number of deaths during a particular period of time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospitalization cost</measure>
    <time_frame>1 month</time_frame>
    <description>Expense of acute pancreatitis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acute Pancreatitis</condition>
  <condition>Complication</condition>
  <arm_group>
    <arm_group_label>Indomethacin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin SR</intervention_name>
    <description>Indomethacin SR 50mg given q12h from admission day 1 to day 7</description>
    <arm_group_label>Indomethacin group</arm_group_label>
    <other_name>YINDUOMEIXIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7</description>
    <arm_group_label>Standard group</arm_group_label>
    <other_name>sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients ages 18-75 years admitted to Peking Union Medical College Hospital&#xD;
             (PUMCH) with a diagnosis of AP based on at least 2 of the following criteria:&#xD;
&#xD;
          -  Abdominal pain characteristic of AP&#xD;
&#xD;
          -  Serum amylase and/or lipase ≥ 3 times the upper limit of normal&#xD;
&#xD;
          -  Characteristic findings of AP on abdominal CT scan will be screened for study&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Onset time &gt;48 hours&#xD;
&#xD;
          -  Presence of renal dysfunction (serum creatinine &gt; 1.5 *normal upper limit)&#xD;
&#xD;
          -  Active peptic ulcer disease or GI bleeding&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Use of daily antiplatelet or anticoagulant drug(s) within 2 week of presentation&#xD;
&#xD;
          -  Hypersensitivity to NSAIDs&#xD;
&#xD;
          -  New-onset, exacerbation or uncontrolled hypertension&#xD;
&#xD;
          -  Presence of serious cardiovascular events, including severe heart failure, myocardial&#xD;
             infarction (MI) and stroke&#xD;
&#xD;
          -  Mental disability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Wu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Wu, M.D.</last_name>
    <phone>8618612671010</phone>
    <email>dongwu@pumc.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Wu, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=25872171</url>
    <description>A small sample study of NSAIDs for treatment of acute pancreatitis</description>
  </link>
  <results_reference>
    <citation>Gorsky VA, Agapov MA, Khoreva MV, Leonenko IV. The effect of lornoxicam on TLR2 and TLR4 messenger RNA expression and tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion in patients with systemic complications of acute pancreatitis. Pancreas. 2015 Jul;44(5):824-30. doi: 10.1097/MPA.0000000000000344.</citation>
    <PMID>25872171</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>December 12, 2018</last_update_submitted>
  <last_update_submitted_qc>December 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>DONG WU</investigator_full_name>
    <investigator_title>Associate Professor of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Acute pancreatitis</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Organ dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

